- Selecting therapy for high risk ER+ HER2- breast cancer in the adjuvant and early relapse setting
- Tailoring Selection of molecularly-guided therapy for advanced ER+ HER2 neg breast cancer
- Real World Oncology: Translating Data to Clinical Practice
- Antibody-Drug Conjugates (ADC): Engineering a New Future for Metastatic Breast Cancer
- Strategies to select: Review of prospective and retrospective sequencing trials in metastatic breast cancer
- ASCO 2025 updates
- Live Q&A
OncLive® State of the Science Summit™ Breast Cancer
Aloft Buffalo Downtown
500 Pearl Street
Buffalo, New York 14202
United States
Wednesday, October 8, 2025
6:00 PM-9:00 PM ET
Complimentary Parking
In-Person Only
Event Chair
Sheheryar Kabraji, BMBCh
Roswell Park Comprehensive Cancer Center
IN PARTNERSHIP WITH
OVERVIEW
OncLive® State of the Science Summit™ (SOSS) are in-person meetings designed for academic & community-based physicians and health care professionals that provide education on the science driving updates in cancer management and the associated clinical benefits for patients. SOSS attendees will improve their knowledge of novel treatment approaches and reinforce their confidence in applying state-of-the-art treatment strategies.
Registration for this Summit is complimentary.
TOPICS INCLUDE:
Venue Location
OncLive - an MJH Life Sciences brand
Copyright 2025 (C) Intellisphere, LLC
2 Commerce Drive
Cranbury, NJ 08512